Dextroamphetamine
Research News and Information

Saturday, November 21, 2009

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.

30 Aug 2009 OBJECTIVE: To evaluate the pharmacokinetics of lisdexamfetamine dimesylate (LDX), a long-acting prodrug stimulant, and mixed amphetamine salts extended-release (MAS XR), alone or with omeprazole, a proton pump inhibitor (PPI). METHODS: This ... Read more...

Sudden death and use of stimulant medications in youths.

13 Jun 2009 OBJECTIVE: The authors sought to determine whether a significant association exists between the use of stimulants and the rare event of sudden unexplained death in children and adolescents. METHOD: A matched case-control design was performed. ... Read more...

Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure.

5 Jun 2009 AIMS: This study investigated the role of the cannabinoid CB1 receptor agonist, WIN 55,212-2, on motor activity. Subsequently, the effects of a low, stimulatory dose of WIN 55,212-2 and cocaine, as a positive control, were evaluated using a ... Read more...

Latest indexed articles for 'Dextroamphetamine'

These are the very latest articles for this heading:

• Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. 30 Aug 2009
• Sudden death and use of stimulant medications in youths. 13 Jun 2009
• Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. 5 Jun 2009
• Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test. 30 May 2009
• The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. 29 Apr 2009
• Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting. 29 Apr 2009
• A novel operant conflict procedure using incrementing shock intensities to assess the anxiolytic and anxiogenic effects of drugs. 29 Apr 2009
• Treatment for amphetamine withdrawal. 13 Apr 2009
• The GABA-B antagonist 2-hydroxysaclofen reverses the effects of baclofen on the discriminative stimulus effects of D-amphetamine in the conditioned taste aversion procedure. 6 Apr 2009
• Community structure in networks of functional connectivity: resolving functional organization in the rat brain with pharmacological MRI. 31 Mar 2009
• The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists. 30 Mar 2009
• Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. 30 Mar 2009
• Dopamine modulates effort-based decision making in rats. 30 Mar 2009
• Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. 25 Mar 2009
• The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. 3 Mar 2009
• Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. 27 Feb 2009
• Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. 22 Feb 2009
• Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. 17 Feb 2009
• Is there a role for psychostimulants in old age depression and apathy? 14 Feb 2009
• Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. 9 Feb 2009

See a longer list of these articles.

Technical information about 'Dextroamphetamine'

Definition: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

Chemical name: Benzeneethanamine, alpha-methyl-, (S)-

Registry Number: 51-64-9

Descriptor UI: D003913

Alternative terms: Dextroamphetamine; dextro-Amphetamine; dextro Amphetamine; Dexamphetamine; d-Amphetamine; d Amphetamine; Dexamfetamine; Oxydess; Vortech Brand of Dextroamphetamine Sulfate; Dextroamphetamine Sulfate; Sulfate, Dextroamphetamine; d-Amphetamine Sulfate; d Amphetamine Sulfate; Dextro-Amphetamine Sulfate; Dextro Amphetamine Sulfate; DextroStat; Shire Brand of Dextroamphetamine Sulfate; Curban; Pasadena Brand of Dextroamphetamine; Dexedrine; GlaxoSmithKline Brand of Dextroamphetamine Sulfate; Mallinckrodt Brand of Dextroamphetamine Sulfate; Celltech Brand of Dextroamphetamine Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Uptake Inhibitors; Central Nervous System Stimulants;

Tree Number: D02.092.471.683.152.110.200;

Online Note: use DEXTROAMPHETAMINE to search DEXTRO AMPHETAMINE 1966-76

History Note: 77; was DEXTRO AMPHETAMINE 1963-76